
ADiTx Therapeutics ADTX
ADiTx Therapeutics Depreciation & Amortization | ADTX
Annual Depreciation & Amortization ADiTx Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 269 K | 614 K | 435 K | 429 K | 369 K | 17.8 K | - | - | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 614 K | 17.8 K | 356 K |
Quarterly Depreciation & Amortization ADiTx Therapeutics
| 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 834 | 833 | 833 | 834 | 833 | - | 833 | 833 | 833 | 27.3 K | 26.8 K | 26.8 K | 26.8 K | 26.8 K | 26.8 K | 26.8 K | 26.8 K | 27 K | 27 K | 26.7 K | 26.4 K | 15 K | 2.8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.3 K | 833 | 15.7 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
41 K | - | -5.38 % | $ 6.06 M | ||
|
Generation Bio Co.
GBIO
|
4.93 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-339 K | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
2.29 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
1.2 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
2.17 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Galapagos NV
GLPG
|
55.9 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1 K | - | -4.36 % | $ 27 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
83 K | $ 4.63 | 21.05 % | $ 20 M | ||
|
Achieve Life Sciences
ACHV
|
228 K | $ 6.78 | 0.89 % | $ 296 M | ||
|
Leap Therapeutics
LPTX
|
5 K | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
44 K | - | - | $ 35.3 M | ||
|
Axcella Health
AXLA
|
412 K | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
295 K | - | - | $ 24.2 M | ||
|
Myovant Sciences Ltd.
MYOV
|
1.38 M | - | -0.04 % | $ 2.62 B | ||
|
Idera Pharmaceuticals
IDRA
|
100 K | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
1.06 M | - | - | $ 69.7 B | ||
|
Atreca
BCEL
|
5.46 M | - | -11.76 % | $ 5.79 M | ||
|
Guardion Health Sciences
GHSI
|
19.4 K | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
94.5 K | - | - | $ 109 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
1.78 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
257 K | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
30 K | - | - | $ 591 K | ||
|
Navidea Biopharmaceuticals
NAVB
|
48.2 K | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
77 K | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
257 K | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
274 K | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
60.3 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
577 K | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
1.2 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
154 K | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
1.26 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
347 K | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
2.22 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
3.9 M | $ 84.95 | 0.13 % | $ 7.99 B |